NEWS RELEASE FOR IMMEDIATE RELEASE

Media contact: Eileen Leahy Elsevier +1 732 238 3628 [email protected]

“Look before you leap:” Cardiologists warn about the risks of vaping

Investigators conclude that electronic cigarettes are far from harmless, and additional regulations are needed to restrict availability to young people, reports the Canadian Journal of Cardiology

Philadelphia, April 12, 2021 – Electronic cigarette (EC) use, or vaping, has both gained incredible popularity and generated tremendous controversy, but although they may be less harmful than tobacco cigarettes (TCs), they have major potential risks that may be underestimated by health authorities, the public, and medical professionals. Two cardiovascular specialists review the latest scientific studies on the cardiovascular effects of cigarette smoking versus ECs in the Canadian Journal of Cardiology, published by Elsevier. They conclude that young non-smokers should be discouraged from vaping, flavors targeted towards adolescents should be banned, and laws and regulations restricting their availability to our youth should be passed and strictly enforced.

Arash Nayeri, MD, and Holly Middlekauff, MD, of the David Geffen School of Medicine at UCLA, Department of Medicine, Division of Cardiology, Los Angeles, CA, USA, have written this review to provide physicians with an objective, rather than emotional, assessment of the available scientific data about ECs so that these physicians can help their patients make informed and thoughtful decisions.

TCs are lethal, killing up to half the people who use them. They are a leading cause of preventable cardiovascular morbidity and mortality around the globe, projected to account for an estimated eight million deaths annually worldwide by 2030, most of which resulting from cardiovascular disease.

ECs have gained popularity since 2007, both among long-term TC smokers and youth who have never smoked tobacco. There is evidence that ECs are less harmful than TCs, and the absence of a number of known toxic byproducts of TCs has helped cultivate the perception that ECs are healthy (or at least benign).

A recent review of more than 50 scientific studies involving over 12,000 participants concluded that ECs are more effective for smoking cessation than certified nicotine replacement therapy (NRT) like patches or gum and were also more effective than behavioral support alone, thereby providing a potential alternative to lethal cigarettes for adult smokers addicted to nicotine. However, there is growing concern that some of their constituents, including nicotine, and their thermal degradation byproducts, may have adverse effects.

“EC vaping by our youth has become so popular that it is approaching a public health crisis,” explain the authors. “Fast on its heels is the recent rapid rise in vaping marijuana. In fact, more youth use marijuana, including vaping it, than currently smoke cigarettes. We have got to get this under control, and the first step in doing so is to know the facts.”

Caption: The Pyramid of Cardiovascular Risk. Nicotine delivery systems, including nicotine replacement therapies (NRTs), smokeless tobacco, electronic cigarettes (ECs) and combusted tobacco, can be ranked within a pyramid of cardiovascular harm, stratified by potency of nicotine delivery and the accompanying non-nicotine toxicants. NRTs have the least cardiovascular risk, and combustible tobacco products have the greatest risk. Smokeless tobacco produces and ECs likely have intermediate cardiovascular risk (Credit: Holly Middlekauff, MD).

Dr. Nayeri and Dr. Middlekauff evaluate:

• Evolution in devices and nicotine delivery of ECs • Cardiovascular effects of nicotine • Non-nicotine constituents and byproducts and biomarkers of cardiovascular risk • Effects of ECs on hemodynamics, arrhythmogenicity, oxidative stress and Inflammation, thrombogenesis, and vascular health • ECs as effective tools to reduce tobacco smoking • Public health implications of tobacco smoking versus vaping • Emergence of pod-like devices • EVALI (EC, or vaping, product use associated lung injury)

It has been calculated that 1.6 to 6.6 million American lives could be saved over 10 years by switching from TCs to ECs. However, the authors point out that the long-term risks of ECs are still unknown and recommend use for the shortest effective time. They also note that fourth generation devices, “pods,” can deliver similar amounts of nicotine as combustible cigarettes by employing “nicotine salts.” Each pod may contain a nicotine load equivalent to a pack of cigarettes, and thus may pose a greater risk of addiction to non-smokers than earlier generation devices. On the other hand, these pod-like devices replicate the nicotine delivery of combustible cigarettes, and thus may have more appeal to smokers addicted to nicotine who want to quit tobacco cigarettes.

The authors point out that smoking one to three cigarettes a day has almost the same cardiovascular risk as smoking one to three packs per day, so using ECs to cut down on smoking (rather than eliminate it) is not an effective strategy. Therefore, they recommend that TC smokers who want to quit and who have failed certified, conventional therapies may consider ECs, but should use them to replace TCs completely.

“Only with great caution and after exhausting all other smoking cessation strategies should we consider recommending that our TC smoking patients switch to ECs,” comments Dr. Nayeri. “Switching to unregulated ECs, with all their promise as smoking cessation devices, may lead to unforeseen, potentially fatal consequences. As currently marketed without quality control, ECs are no panacea,” caution the authors.

Since ECs are not harmless, non-smokers, especially adolescents and young adults, should not use them, say the authors. “The direct marketing to young never smokers and the development of thousands of dessert and candy flavored liquids have unconscionably attracted millions of children to try them,” notes Dr. Middlekauff. To discourage young non-smokers from vaping, the authors propose that flavors should be banned, public health anti-vaping campaigns should be supported, and laws and regulations restricting their availability to young people should be passed and strictly enforced. They also strongly recommend that people should stay away from bootlegged or black-market nicotine- or marijuana-based EC products.

“Look before you leap,” writes Andrew L. Pipe, CM, MD, Division of Cardiac Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, ON, Canada, in an accompanying editorial.

Dr. Pipe points out that despite limited evidence to support the use of electronic nicotine delivery systems (ENDS) for smoking cessation in recent clinical studies, evidence of successful cessation in “real world” settings is not apparent. “Nonetheless, the use of ENDS containing known quantities of nicotine and limited flavoring might facilitate their use for smoking cessation, however, in the absence of appropriate product regulation such clinical use is unlikely in the near future.”

Commenting on the policy vacuum in Canada that allowed the virtually unregulated entry of ENDS into Canada in contrast to the situation in other jurisdictions, Dr. Pipe notes the government’s lack of consideration of their attractiveness to youth and limited regulation of their content, marketing and merchandising, contributing factors to widespread use and abuse of ENDS in Canada. Outcries from parents, educators, clinicians, and health organizations like the Heart and Stroke Foundation of Canada are now resulting in regulatory proposals.

“Will we be replacing the burden of lung- and other smoking-related cancers with an unanticipated burden of differing forms of chronic, incapacitating respiratory disease in years to come?” concludes Dr. Pipe. “Many who anticipated the arrival of ENDS with an optimistic curiosity now recognize the unfortunate realities that have surrounded their largely unregulated arrival. Perhaps some leapt – before they looked.”

---

Notes for editors The article is “Vaping Instead of Cigarette Smoking: A Panacea or Just Another Form of Cardiovascular Risk?” by Arash Nayeri, MD, and Holly Middlekauff, MD (https://doi.org/10.1016/j.cjca.2020.12.008).

This work was supported by the Tobacco-Related Disease Research Program (TRDRP) under the contract numbers TRDRP 28IR-0065 (HRM), TRDRP T29IP0319 (HRM), and TRDRP T31IP1813 (HRM).

The editorial is “Vaping, Smoking Cessation, and Harm Reduction? Look Before You Leap,” by Andrew L. Pipe, CM, MD (https://doi.org/10.1016/j.cjca.2021.02.002).

These articles appear online ahead of the Canadian Journal of Cardiology, volume 37, issue 5 (May 2021) published by Elsevier.

Full text of the articles is available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 238 3628 or [email protected] to obtain copies. Journalists wishing to speak to the review’s authors should contact Holly Middlekauff, MD, at [email protected]. To reach the Dr. Andrew L. Pipe, CM, MD, for comment, please email him at [email protected].

About the Canadian Journal of Cardiology The Canadian Journal of Cardiology is the official journal of the Canadian Cardiovascular Society. It is a vehicle for the international dissemination of new knowledge in cardiology and cardiovascular science, particularly serving as a major venue for the results of Canadian cardiovascular research and Society guidelines. The journal publishes original reports of clinical and basic research relevant to cardiovascular medicine as well as editorials, review articles, case reports, and papers on health outcomes, policy research, ethics, medical history, and political issues affecting practice. www.onlinecjc.ca

About the Editor-in-Chief Editor-in-Chief Stanley Nattel, MD, is Paul-David Chair in Cardiovascular Electrophysiology and Professor of Medicine at the University of Montreal and Director of the Electrophysiology Research Program at the Montreal Heart Institute Research Center.

About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com